Skip to main content
Clinical Trials/NCT07480460
NCT07480460
Completed
Not Applicable

Frontostriatal Connectivity and Gene Expression in Exercise-induced Relief of Back Pain

McGill University1 site in 1 country57 target enrollmentStarted: March 31, 2017Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
57
Locations
1
Primary Endpoint
Chronic Low Back Pain Intensity

Overview

Brief Summary

This study is registered retrospectively for transparency. This mechanistic randomized controlled trial examined whether a 14-week supervised physical exercise training program reduces chronic low back pain (CLBP) by modulating frontostriatal brain connectivity and immune-related gene expression. Fifty-seven adults with CLBP were randomized to exercise training or wait-list control. Participants underwent pre- and post-intervention MRI, questionnaires, and blood sampling. The study tested whether reductions in nucleus accumbens-medial prefrontal cortex connectivity and changes in inflammatory gene expression mediated exercise-induced pain relief.

Detailed Description

Chronic low back pain (CLBP) is associated with altered functional connectivity between the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), as well as systemic low-grade inflammation.

This mechanistic randomized controlled trial evaluated the effects of a 14-week supervised physical exercise (PE) training program on pain intensity, functional disability, brain connectivity, and peripheral gene expression in individuals with CLBP.

Participants were randomized to either:

  • Supervised exercise training (3 sessions per week, 60 minutes per session, 14 weeks), or
  • Wait-list control.

Exercise sessions combined aerobic and resistance training. Exercise intensity was individually calibrated based on VO2max and 1 repetition maximum (1RM) assessments.

Assessments conducted pre- and post-intervention included:

  • Resting-state functional MRI
  • Diffusion-weighted imaging
  • Self-reported pain and disability questionnaires
  • Cardiorespiratory and functional testing
  • Blood sampling for BDNF and RNA sequencing

The primary mechanistic hypothesis tested whether changes in NAc-mPFC connectivity and immune-related gene expression mediated exercise-induced reductions in chronic pain. Therefore, primary outcomes focused on indices of target engagement (including immune gene expression and brain connectivity) rather than clinical efficacy alone.

Note: This study was not registered prior to participant enrolment. The project was investigator-initiated and conceived as a mechanistic investigation prior to widespread mandatory registration requirements. Study recruitment and progress were also substantially influenced by the COVID-19 pandemic and associated lockdowns.

The clinical efficacy of PE for CLBP is already well established. Consequently, the primary aim of the present study was to examine the biological mechanisms through which PE may influence pain. Registration is therefore being completed retrospectively to ensure transparency.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years
  • Chronic low back pain ≥ 3 months
  • Pain present at least half the days over the past 6 months
  • Average pain intensity ≥ 3/10 during week prior to enrollment

Exclusion Criteria

  • Neurological disorder
  • Psychiatric disorder
  • Significant cardiorespiratory disease
  • Under 18 years of age

Arms & Interventions

Active intervention

Experimental

Physical exercise training

Intervention: Supervised physical exercise training (Behavioral)

Waitlist control

No Intervention

Participants underwent all assessments but did not receive exercise training during the 14-week study period.

Outcomes

Primary Outcomes

Chronic Low Back Pain Intensity

Time Frame: Assessed at Baseline (Pre-intervention, Week 0) and Post-intervention (Week 14)

Self-reported average low back pain intensity measured using an 11-point Numerical Rating Scale (NRS; 0-10), where 0 = "no pain" and 10 = "worst imaginable pain."

Secondary Outcomes

  • Oswestry Low Back Pain Disability Index (ODI)(Assessed at Baseline (Week 0) and Post-intervention (Week 14))
  • Whole-Brain Intrinsic Connectivity(MRI acquired at Baseline (Week 0) and Post-intervention (Week 14))
  • Nucleus Accumbens-Medial Prefrontal Cortex Functional Connectivity(MRI acquired at Baseline (Week 0) and Post-intervention (Week 14))
  • Fractional Anisotropy of NAc-mPFC White Matter Tract(MRI acquired at Baseline (Week 0) and Post-intervention (Week 14))
  • Peripheral Blood Gene Expression (RNA Sequencing)(Blood samples collected prior to Session 7 (first calibrated-intensity session, Week 3) and prior to Session 42 (final session, Week 14))
  • Plasma Brain-Derived Neurotrophic Factor (BDNF)(Collected immediately before and after Session 7 (Week 3) and immediately before and after Session 42 (Week 14))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mathieu Roy

Professor

McGill University

Study Sites (1)

Loading locations...

Similar Trials